Rocket Pharmaceuticals said its existing funds are expected to support operations through the third quarter of 2028, while the company prepares to bring its gene therapy KRESLADI to market. The pace of patient starts at treatment centers and pivotal data from its cardiovascular program RP-A501 remain important tests of whether development progress can translate into lasting commercial value.
Lower quarterly costs, with financing lifting cash
Rocket held about $279.4 million in cash, cash equivalents and investments at the end of September 2026, up from $188.9 million at the end of 2025. The increase did not come entirely from operations: the company received about $180 million from selling a priority review voucher in June, and its balance sheet also includes the first $35 million draw under a Hercules credit facility. Total liabilities were about $92.8 million, compared with $53.2 million at the end of December 2025.
Management expects the current funds to cover operations through the third quarter of 2028. The Hercules agreement provides for up to about $150 million, but Rocket has drawn only $35 million so far. Further draws depend on optional draw periods and clinical milestones, so the potential additional funding is subject to conditions. Cash burn and any need for further financing will remain in focus as KRESLADI commercialization advances.
Research and development expenses fell about 8.5% year over year in the third quarter, to $31.2 million from $34.1 million. Rocket attributed the decline mainly to a smaller research workforce and a roughly $3.5 million reduction in stock-based compensation and employee-related costs. Manufacturing and development costs, as well as depreciation, also declined. Higher laboratory and professional-services costs, each up about $1.4 million, and a $600,000 increase in clinical trial expenses offset some of the savings.
General and administrative expenses rose about 7.9%, to $19.8 million from $18.4 million. The increase was driven mainly by $3.4 million in higher costs related to post-listing commitments and $600,000 in commercialization preparation costs, partly offset by lower compensation-related and legal expenses. Total operating expenses declined about 2.5% to $51 million. Rocket reported a net loss of about $49.2 million, or $0.43 per share, compared with a loss of $50.3 million, or $0.45 per share, a year earlier.
KRESLADI targets a small, defined patient population
KRESLADI, whose generic name is marnetegragene autotemcel, received accelerated approval from the U.S. Food and Drug Administration in late March 2026. It is indicated for certain pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I) who do not have an HLA-matched sibling donor for an allogeneic hematopoietic stem cell transplant.
The ex vivo gene therapy is designed to address the genetic defect. A patient’s own hematopoietic stem cells are collected and modified to introduce a functional ITGB2 gene, with the aim of restoring CD18 expression and improving the movement of white blood cells to sites of infection. Treatment involves collecting, modifying and returning the patient’s cells, as well as myeloablative conditioning. It is therefore a complex process rather than a routine medication course.
Rocket estimates that about 25 children in the United States are born with LAD-I each year, around 65% of them with the severe form. Severe disease has a poor prognosis without a transplant; company materials indicate that slightly more than 60% of severely affected children who do not receive a transplant die before age two. Current options are mainly allogeneic stem cell transplantation and supportive care. Donor availability and risks including graft failure, infection and graft-versus-host disease limit treatment choices.
Annual births do not represent the number of patients KRESLADI can reach. Eligibility also depends on disease severity, whether a suitable HLA-matched sibling donor is available, and diagnosis and treatment assessments. The approval was based on increased cell-surface expression of CD18 and CD11a. Maintaining the approval may depend on further evidence of clinical benefit and post-marketing data collection.
Two treatment centers prepare to receive patients
Management said Rocket was ready for commercialization on October 1, 2026, with two qualified treatment centers activated to begin enrolling patients and an external manufacturing network in place. The company is relying on a limited number of specialized centers rather than building a large sales force, a model suited to a small patient population and a complex treatment process.
The next steps include diagnosis and referral, evaluation at treatment centers, cell manufacturing, reimbursement arrangements and infusion. Each can affect the time from diagnosis to treatment and the timing of revenue recognition. Center activation is a commercialization milestone, but it does not establish how many patients have enrolled or been treated. Disclosures on patient starts and treatment volumes will provide a clearer indication of KRESLADI’s initial commercial contribution.
RP-A501 data remain a key pipeline test
The longer-term value of Rocket’s pipeline also depends on its cardiovascular gene therapy programs, including RP-A501 for Danon disease. The company expects to complete dosing in the pivotal RP-A501 trial by mid-2027 and report topline results around mid-2028. Those data will help assess the therapy’s safety and efficacy, as well as the prospects for further development and potential commercialization.
Management estimates that Rocket’s cardiovascular programs together address more than 100,000 patients in the United States and European Union across genetically defined hypertrophic, arrhythmogenic and dilated cardiomyopathies. The company’s U.S. facility in Cranbury, New Jersey, covers about 100,000 square feet, including roughly 50,000 square feet for AAV cGMP manufacturing. The facility and external network provide a foundation for development and potential supply, but manufacturing capacity does not replace clinical evidence on safety and efficacy or proof of commercial viability.
Valuation reflects limited revenue and ongoing development
At the time described, Rocket shares traded at about $2.30, giving the company a market capitalization of roughly $262 million and an enterprise value of about $48 million. With limited commercial revenue and continuing losses, valuation measures reflect the company’s small sales base and development-stage profile. Its price-to-book ratio was about 0.71, below the healthcare industry median of roughly 2.57. Its forward enterprise-value-to-sales ratio was about 43.25, a high multiple against currently limited sales.
Rocket’s funding position gives it room to continue research and commercialization preparation, but its cash balance includes proceeds from the priority review voucher sale and a credit-facility draw, rather than cash generated solely through operations. Investors’ assessment of the pipeline will depend on KRESLADI treatment progress, pivotal RP-A501 results and the company’s future funding needs.